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Abstract: The irreversible loss of functional cardiomyocytes (CMs) after myocardial infarction
(MI) represents one major barrier to heart regeneration and functional recovery. The combination
of different cell sources and different biomaterials have been investigated to generate CMs by
differentiation or reprogramming approaches although at low efficiency. This critical review article
discusses the role of biomaterial platforms integrating biochemical instructive cues as a tool for
the effective generation of functional CMs. The report firstly introduces MI and the main cardiac
regenerative medicine strategies under investigation. Then, it describes the main stem cell populations
and indirect and direct reprogramming approaches for cardiac regenerative medicine. A third section
discusses the main techniques for the characterization of stem cell differentiation and fibroblast
reprogramming into CMs. Another section describes the main biomaterials investigated for stem cell
differentiation and fibroblast reprogramming into CMs. Finally, a critical analysis of the scientific
literature is presented for an efficient generation of functional CMs. The authors underline the need
for biomimetic, reproducible and scalable biomaterial platforms and their integration with external
physical stimuli in controlled culture microenvironments for the generation of functional CMs.
Keywords: biomaterials; cardiomyocytes; differentiation; myocardial infarction; reprogramming
1. Introduction
Myocardial infarction (MI) is caused by the obstruction of coronary arteries, resulting in the
death of approximately 1 billion cardiomyocytes (CMs) in the left ventricle within a few hours,
acute inflammation and degradation of the cardiac extracellular matrix (ECM), with the formation of
a fibrotic scar. Fibrotic tissue is mechanically stiffer than healthy cardiac tissue, it is mainly populated
by cardiac fibroblasts (CFs) and lacks beating CMs [1,2].
Despite significant advances in pharmaceutical and interventional therapies, the irreversible loss
of functional CMs is still a critical issue. After ischemic heart disease, the dense collagenous scar
replacing contractile CMs undergoes progressive negative remodelling, which impacts myocardial
contractility and electrical conduction (Figure 1) [3].
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Figure 1. Left ventricular (LV) enlargement in the post-infarction phase due to thinning and dilation 
of the infarct zone (infarct expansion). Reproduced with permission from Curley et al. [3]. 
This progressively leads to a severe deficiency of the ventricular pump function causing heart 
failure (HF) [4]. HF is the leading cause of mortality and morbidity in the industrialized world with more 
than 23 million cases worldwide and a survival rate of only 50% within 5 years from diagnosis [5,6]. For 
this reason, it has been defined as a global pandemic, accounting for 1–3% of all healthcare 
expenditures in North America, Western Europe and Latin America [7]. Nowadays, the only standard 
therapy for end-stage HF addressing the irreversible loss of CMs is heart transplantation, which however 
is limited by donor loss, risky surgical procedures and need for life-long immunosuppression. 
In this scenario, there is a pressing need for new effective therapies for the functional 
regeneration of myocardial contractility, through the repopulation of the infarcted area with beating 
CMs. Cardiac patches, injectable hydrogels and cell therapy are under investigation as therapeutic 
approaches for myocardial regeneration [2,6,8,9]. However, cell therapy, consisting of the local 
infusion of cells at the infarct site, is constrained by poor cell retention and survival, which results in 
limited therapeutic benefit, mainly attributed to a ‘paracrine effect’ [10,11]. On the other hand, 
patches and hydrogels mechanically reinforce the fibrotic scar tissue and can also stimulate functional 
regeneration by the recruitment of endogenous cells or the delivery of exogenous cells [6]. The first 
strategy known as “endogenous cardiac regeneration” is limited by several constrains, including the 
low proliferative capacity of adult CMs, the limited regenerative potential of resident cardiac stem 
cells and the low number, poor homing ability and questionable in vivo differentiation into CMs of 
circulating bone-marrow derived stem cells [6]. On the other hand, in “exogenous cardiac 
regeneration” strategies, hydrogels and patches are applied as cell carriers and their biochemical, 
structural and mechanical properties may improve cell retention, viability, differentiation and 
integration with the host tissue compared to traditional cell therapies. 
Furthermore, in the last decade, emerging studies have raised a new intriguing possibility for 
myocardial regeneration, represented by the direct reprogramming of fibroblasts into CMs. 
Considering the abundance of cardiac fibroblasts in the heart, the possibility for their direct 
reprogramming is expected to revolutionize therapies for myocardial regeneration by the direct 
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Furthermore, in the last decade, emerging studies have raised a new intriguing possibility
for myocardial regeneration, represented by the direct reprogramming of fibroblasts into CMs.
Considering the abundance of cardiac fibroblasts in the heart, the possibility for their direct
reprogramming is expected to revolutionize therapies for myocardial regeneration by the direct
conversion of dysfunctional fibrotic scar into contractile myocardial tissue [12–16]. Alternatively,
the possibility to directly convert fibroblasts into CMs could also be exploited for in vitro generation of
autologous CMs for the cellularization of implantable hydrogels and patches. In this review, we will
describe the main available cell sources for CM generation, the experimental techniques to evaluate
CM generation at the different levels (early, late, functional) of their maturation as well as the optimal
biomaterial types inducing CM differentiation/reprogramming. Finally, we will critically discuss the
key role of biomaterials in the functional maturation of CMs.
2. Cell Sources for the Generation of Cardiomyocytes
Several cell sources can be employed for CM generation. Below, a brief description of pluripotent
stem cells (embryonic stem cells, ESCs; induced pluripotent stem cells, iPSCs), adult stem cells
(mesenchymal stem cells, MSCs and cardiac progenitor cells, CPCs) and direct/indirect reprogramming
approaches is presented.
2.1. Embryonic Stem Cells (ESCs)
Embryonic stem cells are undifferentiated cells not yet committed to differentiate into any cell type;
they reside within the inner cell mass of embryos at their blastocyst stage and are called blastomeres
until the embryo is implanted into the uterus. Blastomeres can potentially differentiate into any adult
cell type. However, after implantation into the uterus these cells initiate a differentiation process and
reduce their pluripotency [17].
When blastomeres are extracted from the embryo and cultured under specific conditions in vitro,
they can proliferate indefinitely by self-renewal to retain pluripotency [18]. On the other hand,
under specific culture conditions, they can be differentiated in vitro to generate specific cell phenotypes.
ESCs offer high potentialities for new drug testing, regenerative medicine, cell therapies, toxicity
studies and disease systems modelling. ESCs can differentiate into CMs and are one of the most
promising cell sources for cardiac regeneration. Evidences of heart regeneration from human ESCs
have been demonstrated from studies in different animal models, such as pig, guinea pig and
non-human primate models [17,19,20]. However, several ethical constrains hinder the use of ESCs for
clinical research and applications. Firstly, the derivation of these cells from human embryos imposes
an important ethical and legislative challenge. Secondly, ESCs have shown some potential risks
due to their genetic instability and consequent tumorigenicity which, together with their potential
immunogenicity, represent crucial limitations to their use [17]. These issues have been overcome by
a new type of pluripotent stem cells, the induced pluripotent stem cells (iPSCs), described in the
following paragraph.
2.2. Induced Pluripotent Stem Cells (iPSCs)
The iPSCs were firstly introduced by Takahashi and Yamanaka in 2006: they generated stem cells
with similar properties to ESCs starting from adult differentiated cells [21]. In detail, they transduced
skin fibroblasts with a combination of 4 reprogramming factors: Oct4 (Octamer binding transcription
factor-4), Sox2 (Sex determining region Y)-box2, Klf4 (Kruppel Like Factor-4) and c-Myc. Through this
approach, somatic cells were reprogrammed into iPSCs able to self-renew as well as to differentiate
into several cell types, in analogy to ESCs. This discovery had a strong impact in the clinics and
research, as for the first time it made available a population of autologous pluripotent stem cells and
overcame the ethical issues of ESCs.
Takahashi and Yamanaka’s work has been followed by the intense activity of a wide number of
research groups, that proposed other reprogramming factors and/or methods to generate iPSCs with
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different efficiency levels. Singh et al. have recently reviewed the main methods to generate iPSCs [22].
iPSCs can be used in tissue regeneration, drug discovery and disease modelling. For tissue regeneration,
iPSCs obtained from autologous somatic cells are differentiated in vitro and then transplanted at
the injured site or degenerated tissue. A recent work published by Rojas et al. has shown that
murine iPSC-derived CMs can be successfully engrafted in a murine model of myocardial infarction
and such treatment improves murine heart function [23]. The iPSCs-based technology has also
been applied to human cells, to generate human iPSCs for further differentiation into CMs [24].
Such approach makes autologous CMs available for cardiac regeneration and for the obtainment of
patient- and/or mutation-specific models to study cardiac diseases and develop novel personalized
therapeutic strategies. However, iPSC-derived CMs from human cells have shown limited functional
maturation compared to adult human CMs, which may hinder their use in clinical applications.
In general, as reported by Singh et al. the use of iPSCs is also mainly limited by safety concerns
associated with the use of viral vectors for cell transfection, with possible risk for insertional
mutagenesis after transfection [22]. Only once these limitations are overcome, it will be possible
to exploit the enormous potentialities of iPSCs in the clinics.
2.3. Mesenchymal Stem Cells (MSCs)
MSCs are adult stem cells which reside in several mature tissues such as bone marrow, muscle,
fat, synovial membrane, umbilical cord, peripheral blood, amniotic fluid, foetal liver and lung [25].
They are characterized by the capability of self-renewal through cell division and multipotency,
showing the ability to differentiate under certain conditions into a variety of cell types, such as
osteoblasts, adipocytes (fat cells), chondrocytes (cartilage cells), myocytes (muscle cells) for the
regeneration of bone, fat, cartilage and muscle tissues, respectively. MSCs isolated from bone marrow
(BMSCs) have been widely used in regenerative medicine applications due to their low immunogenicity
and immunomodulatory effects, which minimize the immune rejection risk. These properties also
make BMSCs ideal candidates for cardiac regeneration [26,27]. As reported by Miao et al. BMSCs offer
some advantages for therapeutic treatment of cardiac disease, as they may support cardiac regeneration
through paracrine effect, secreting several growth factors, such as cytokines like vascular endothelial
growth factor (VEGF), fibroblast growth factor (FGF), hepatocyte growth factor (HGF), interleukin
(IL)-6, platelet-derived growth factor (PDGF) and insulin-like growth factor (IGF) [27]. In addition,
BMSCs may promote the recovery of cardiac function by inhibiting the inflammatory process.
However, the use of BMSCs is associated with the potential risk to develop malignant spontaneous
transformation, which has been observed mainly in in vitro cell cultures [28]. In addition, only few
clinical trials exist to support the use of BMSCs for cardiovascular disease treatment: for instance,
their clinical application would require the knowledge of the optimal cell dose supporting BMSCs
viability after transplantation at the poorly vascularized infarct area. Other issues and concerns are
related to poor cell engraftment, survival and differentiation of the injected adult stem cells.
2.4. Cardiac Progenitors Cells (CPCs)
CPCs reside within cell niches in atria, ventricles, epicardium and pericardium of the heart and are
characterized by a strong heterogeneity [29]. According to the definition given by Mauretti et al. they are
characterized by self-renewal ability and multipotency. Based on that, CPCs may differentiate into
different cardiac cells such as cardiomyocytes, smooth muscle cells, endothelial cells and fibroblasts [29].
CPCs include different classes of stem cell subpopulations with partially overlapped phenotypic profiles:
c-Kit (or CD117)-positive CPCs, discovered in mouse and then found also in human heart; cardiospheres
and cardiosphere-derived cells (CDCs), clusters generating a great amount of proliferative cells; epicardium
derived cells, the cardiac side population cells; stem cell antigen-1 CPCs; CPCs expressing Islet-1 (Isl-1);
CPCs expressing platelet derived growth factor receptor-alpha (PDGFRα) [30].
A scientific debate has arisen on the role of CPCs on myocardial regeneration. Some researchers
have reported that CPCs are not able to contribute to the formation of new cardiomyocytes [31,32].
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On the contrary, other researchers have evidenced the possibility of heart regeneration after injury
driven by different cell sources including myocytes, c-kit-positive bone marrow cells, c-kit-positive
resident CPCs, cardiospheres, resident fibroblasts and tissue resident mesenchymal stem cells [33–36].
According to this view, CPC recruitment at the infarct area could in principle activate myocardial
tissue regeneration. Alternatively, CPCs have also been transplanted into injured hearts resulting in
improved cardiac function. In detail, several studies have demonstrated that CPCs are able to induce
regeneration of injured heart in different animal models (mainly murine and rat models) [37]. The first
clinical trial (the Cardiac Stem Cell Infusion in Patients with Ischemic Cardiomyopathy—SCIPIO)
has also been performed and results have shown an improvement of the left ventricular systolic
function and a reduction of infarct size [30]. More recently, van Berlo et al. have used genetic
tracing experiments to follow CPC fate after injection and have demonstrated that minimal CMs are
generated from c-Kit-positive CPCs in vivo [38]. In contrast, abundant cardiac ECs were derived from
c-Kit-positive CPCs [38].
Hence, after many years of pre-clinical and clinical investigations, the limited knowledge on
the molecular mechanisms regulating cardiac regeneration makes the debate on CPC role still open.
Currently, based on the most recent findings, the main view is that adult stem cell therapy is responsible
for a paracrine release of growth factors able to induce neovascularization or favourable changes in
the cardiac scar, rather than the formation of new CMs.
2.5. Indirect and Direct Reprogramming
Yamanaka and Takahashi were the pioneers of cellular reprogramming [21]. The method they
proposed was defined as indirect reprogramming, as an adult cell type may be reprogrammed into
a new adult cell type by passing through an intermediate pluripotent (iPSCs) stem cell state, followed
by differentiation into CMs.
On the other hand, in the direct reprogramming approach, the intermediate pluripotent stem
cell stage is not present and one adult cell type can be converted into another adult cell type directly.
Cardiac regeneration may be potentially achieved through direct reprogramming of non-myocyte
cells (fibroblasts) into CMs by administering a set of transcriptional factors (TFs) and/or microRNAs
(miRNAs) and/or small molecules [39–41]. Qian and Srivastava have recently reviewed in vitro and
in vivo direct cardiac reprogramming approaches [39], while Chen et al. have provided an exhaustive
review on direct reprogramming of mouse and human fibroblasts [40]. Different combinations of TFs
and/or miRNAs and/or small molecules and different types of fibroblasts may result in different
reprogramming efficiencies, evaluated by the expression of CM markers and electrophysiological and
beating properties [40]. Factors mainly used to directly reprogram human cardiac fibroblasts into CMs
are TFs, such as Gata4, Mef2c, Tbx5 and Hand2, able to induce rapid and efficient reprogramming of
adult cardiac and dermal fibroblasts into cardiomyocyte-like cells [42,43]. Other epigenetic regulators,
such as miRNAs and signalling proteins have shown their ability to regulate direct reprogramming [44].
Also, combinations of miRNAs can be used, as suggested by recent studies by Jayawardena et al. [45].
In detail, a set of four miRNAs (miR-1, miR-133, miR-208 and miR-499) has demonstrated the ability to
directly reprogram fibroblasts into cardiomyocyte-like cells, showing CM properties and expression
markers [45]. Moreover, the suppression of pro-fibrotic signals using small molecules has been reported
to favour fibroblast reprogramming into CMs. Zhao et al. have shown that targeting the transforming
growth factor-β (TGF-β) and Rho-associated kinase (ROCK) pathways in combination with exogenous
expression of core cardiac TFs can improve fibroblast reprogramming into CMs with an efficiency up
to 60% [43].
In addition to the possibility to directly convert fibroblasts into CMs, novel direct reprogramming
approaches have been recently proposed to reprogram fibroblasts into induced CPCs, although less
investigated [46]. One advantage of this approach is the proliferative behaviour of CPCs and their
potential ability to differentiate into all the cell types populating the heart.
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Direct cardiac reprogramming is one of the most recent approaches in the field of cell therapy
applied to cardiovascular disease research and treatment. Even if it is at an early stage compared to
other strategies, direct reprogramming presents several advantages, including the absence of ethical
issues and the wide potential applications, from drug testing to disease modelling and regenerative
medicine. However, further studies are needed to demonstrate the efficacy and safety of this strategy
in animal models before translation into humans.
2.6. New Emerging Approaches for CM Generation
Studies performed on non-mammalian vertebrates, such as zebrafish, have demonstrated that this
animal model possesses enhanced capacity for heart regeneration [47]. Zhang et al. have shown that
cardiac regeneration in zebrafish, using a ventricle-specific ablation system, is driven by pre-existing
cardiomyocytes, particularly through the trans-differentiation of atrial cardiomyocytes into ventricular
ones [47]. Although this topic will not be discussed in detail in this review, these findings have raised
the question if these cardiac regenerative strategies can also be induced in the human heart. In this
context, Giacca et al. have been the pioneers in the study of methods to stimulate the proliferation of
adult CMs [48,49]. They have found that CM behaviour is under the control of microRNA network: some
endogenous microRNAs (e.g., miR-1) regulate CM expansion; others are able to induce the de-differentiation
of CMs into a pluripotent phenotype (e.g., the miR-302/367 cluster); others hinder CM proliferation
(e.g., the miR-15 family). Furthermore, some microRNAs have not a physiological role in CMs but when
administered exogenously they affect CM proliferation (e.g., miR-199a-3p). Recently, Zacchigna et al. have
also found that proliferating CMs are present in both maternal and foetal heart during pregnancy [50].
They have demonstrated that CM proliferation is regulated by a set of factors secreted by regulatory T cells:
Cst7, Tnfsf11, Il33, Fgl2, Matn2 and Igf2 [50].
All these emerging studies are aimed at finding out a combination of therapeutics able to stimulate
endogenous cardiac regeneration through the induction of adult CM proliferation.
3. Techniques for the Evaluation of the Formation of Functional Cardiomyocytes
In the last decades, the generation of CMs by cell differentiation and reprogramming approaches
has spread out to meet the demand for specific therapies to treat MI. Although significant results
have been obtained and CMs generated by such approaches display cardiomyocyte-related markers
and functions, they are still far from full maturation. In this paragraph, the main characterization
techniques allowing quantification of CM maturation are described. Peculiar adult CM characteristics
can be grouped into five main categories: gene expression, cell morphology and structural organization,
calcium handling, electrophysiological properties and oxidative metabolism [51].
One of the leading and easiest approaches to assess CM maturation is gene expression by
RT-PCR analysis. In detail, the induction of cell commitment into cardiac lineage is suggested by
the expression of Gata-4, Tbx5, Mef2c, Hand2 and Nkx2.5 TFs. During embryonic life, these TFs
are essential for the correct differentiation and patterning of the heart and their loss of function
causes human congenital heart disease [52]. Gata-4 is considered a pioneer cardiac TF, which opens
chromatin structure in cardiac loci, acts jointly with the other TFs and enables subsequent activation
of specific cardiac target genes [53]. The expression of these TFs can be observed in the first days of
differentiation/reprogramming process in vitro and their different combinations have been frequently
used to drive cardiac lineage commitment of stem cells and fibroblast reprogramming in vitro [43,54].
As CM maturation in vitro progresses, an increase in MHY7 expression, encoding for β-myosin heavy
chain (β-MHC), relative to MYH6 expression, encoding for α-MHC, as well as the isoform switch
of specific structural proteins, such as slow skeletal troponin I (ssTnI) to cardiac troponin I (cTnI)
can be observed [55]. In addition, the activation of genes encoding for calcium handling, such as
SERCA2 and CACNA1C and sodium/potassium channels, such as KCNJ12 indicates the in vitro
differentiation toward a mature CM phenotype [56]. Despite most of these genes are present in CMs
generated in vitro, their expression levels are lower than for adult CMs: key differences are mostly
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detected in cardiac ion channel and calcium handling genes, highlighting the immature phenotype of
in vitro generated CMs [57].
Cell morphology and structural organization are also characterized to evaluate CM maturation.
Adult CMs have a rod-shaped architecture and are aligned in culture, whereas CMs generated in
culture have an irregular morphology and do not present cell alignment when cultured in vitro.
Particularly, pluripotent stem cells-derived CMs have circular or triangular morphology and are
significantly smaller compared to mature CMs [58]. Moreover, polyploidy is a characteristic of adult
CMs: nearly 33% of adult CMs present more than one nucleus, whereas in vitro generated CMs are
mostly mononucleated.
Sarcomere formation should also be evaluated [59]. Sarcomere is the fundamental unit for
CM contraction and it is identified by the expression of contractile/myofilament proteins, such as
α-sarcomeric actinin and β-MHC and regulatory proteins which modulate the activation of muscle
contraction, such as tropomyosin and the cardiac troponin complex T (cTnT), C (cTnC) and I (cTnI) [60].
Both cellular (immunocytochemistry) and molecular (RT-PCR) -based analyses are used to evaluate
the expression of these markers. For a deeper and complete study, sarcomere structure should be
confirmed by electron microscopy. Adult CMs present a well-organized sarcomeric structure whose
length reaches 2.2 µm (in relaxed adult human cardiac muscle cells), whereas iPSC-derived CMs have
an immature sarcomeric organization of approximately 1.65 µm length [58].
Furthermore, calcium handling is important to determine CM maturation. Human adult CMs
store calcium in the sarcoplasmic reticulum (SR). The commonly used markers to identify the
presence of the SR are the regulatory proteins calsequestrin and phospholamban. Calsequestrin,
involved in calcium binding and storage in the SR and phospholamban, which modulates SR Ca2+
sequestration, are expressed at abnormal levels or nearly absent in in vitro generated CMs [59].
Moreover, the formation of transverse tubules (T-tubules), which consist of membrane invagination
along the Z-line regions of the cells, contributes to CM maturation. T-tubules allow synchronous
triggering of SR calcium release and therefore, the propagation of cardiac action potential into the
entire cytoplasm, thus initiating the process of excitation-contraction (EC) coupling [61].
Nowadays, the electrophysiology of in vitro generated CMs varies among different studies, depending
on differentiation methods, cell types and culture times. Immature CMs have a higher resting membrane
potential of about −60 mV compared to −90 mV displayed by mature CMs. Membrane depolarization
in adult CMs is extremely fast (300 V/s in healthy hearts), whereas in vitro generated CMs show lower
depolarization speed. The conduction velocity increases as the heart matures from 0.3 m/s to 1 m/s for
neonatal and adult CMs, respectively. Zhu et al. have demonstrated that human ESC-CM conduction
velocity is increased as in vitro cell maturation proceeds but still lower compared to embryonic CMs [62].
Additionally, the distribution of gap junctions is an important factor that regulates conduction velocity.
During embryonic life, the gap junction protein Connexin 43 (Cx43) and the adhesion protein N-cadherin
(N-cad) are distributed along the cell circumference, while in post-natal heart they tend to concentrate
at the cell-cell junction, thus resulting in accelerated conduction velocity of CMs [63]. Wang et al. have
shown that mouse iPSC-CMs cultured in vitro for 28 days express Cx43 in the cytoplasm but on the
cellular membrane [64].
Finally, metabolic changes during CM maturation are important hallmarks that should be
considered. During early stages of cardiac development, the major source of energy in embryonic CMs
is glycolysis (nearly 80%). As CM maturation proceeds, cells switch their metabolic features to fatty
acid-β oxidation, which generates a more energetic profile [55]. To satisfy the high energetic need,
mitochondria occupy at least 30% of total adult CM volume [65]. Conversely, energy source in CMs
obtained in vitro is based on glycolysis rather than on fatty acid–β oxidation, hence mitochondria
are localized next to the nucleus or cell periphery instead of along myofibrils as in adult CMs.
Zhou et al. have shown that iPSC-CMs generated from mouse cardiac fibroblasts displayed increased
expression of genes related to glycolysis, whereas CMs induced by direct reprogramming of fibroblasts
showed higher expression of genes involved in fatty acid-β oxidation [66].
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In conclusion, the generation of mature and functional CMs in vitro that reflect the physiological
characteristics of human adult CMs is difficult to be obtained and requires further progress. For this
reason, different in vitro culture conditions that closely mimic the cardiac environment are under study
to increase the yield of in vitro CM maturation.
4. Biomaterials for Guiding Cell Behaviour
Cell differentiation into a certain mature cell type is achieved in vivo by complex and multistep
processes which are regulated by both intrinsic and extrinsic cell mechanisms [67,68]. Intrinsic factors
are the genetic and molecular signatures expressed by the cells. Over the last decades, increasing
evidences have suggested that also external stimuli from the surrounding microenvironment, including the
extracellular matrix (ECM), contribute to the overall control of stem cell activity (extrinsic mechanisms) [69].
In detail, ECM stiffness, organization, biochemistry and embedded signalling molecules have been found
to influence cell fate [70,71]. These signals are transduced intracellularly through specific interactions,
mainly based on integrin receptors [72].
In the heart, ECM is a complex structure, which provides a crucial environment maintaining CM
functions. Main cardiac ECM components include: glycosaminoglycans (GAGs) and proteoglycans
as important structural molecules, different collagen proteins (collagen Type I, III and V) to provide
elasticity and structural integrity to cardiac tissue and fibronectin, which interacts with integrins,
GAGs and collagens to mediate cellular adhesion [73]. Several studies have reported in vitro stem cell
differentiation into CMs on 2D tissue culture plates (TCPs). However, such approaches have generally
failed in generating mature CMs, as in vitro generated CMs have generally shown characteristics
closer to foetal than adult CMs [74]. Ideal culture conditions should not only support cell adhesion
and growth but also provide an environment which mimics the native one where cells are able to
express their in vivo phenotype features [75]. For this reason, traditional 2D cell culture methods have
been overcome by new approaches. Currently, cardiac tissue engineering strategies are addressed
to the development of 3D biomimetic substrates, which resemble the physiological environment for
cell adhesion, proliferation and differentiation [76]. A variety of biomaterials have been used for the
purpose, both from natural and synthetic origin [77]. Biomaterials can guide cell behaviour through
their biochemical (composition) and physical (mechanical, electrical, structural) properties [78–80].
Particularly, in this work, the role of biochemical signalling exerted by different biomaterials on cell
differentiation and reprogramming into CMs is highlighted.
Mostly used biomaterials for CM generation can be divided into three main categories:
(i) ECM-mimetic (mainly protein-based) biomaterials;
(ii) decellularized cardiac ECM;
(iii) “bioartificial” materials consisting of synthetic polymers functionalized with cardiac ECM proteins.
Biomaterials based on ECM components include: (i) cardiac ECM proteins, such as collagen and
its derivative gelatin, laminin and fibronectin, isolated from animal or human tissues or derived from
recombinant sources; (ii) natural polymer mixtures, such as Matrigel, a soluble basement membrane
biomaterial extracted from Engelbreth-Holm-Swarm mouse tumours and Cardiogel, a cardiac ECM,
deposited by in vitro culture of neonatal rat cardiac fibroblasts and consisting of collagen Type I and
III, laminin and fibronectin [81,82]. However, obtaining a substrate that functionally resembles the
intrinsic complexity of native cardiac ECM still represents a challenge [83].
Different studies have overcome this problem by using decellularized cardiac ECM [84]. Decellularized
scaffolds offer an ideal environment, as they preserve the architecture of the whole organ as well as
cell-binding domains, which are functional for cell adhesion, proliferation and migration [85].
Furthermore, several synthetic polymer-based substrates have been used for cardiac tissue
regeneration in the last decades [86]. Synthetic polymer substrates can be easily fabricated and
finely tuned to obtain scaffolds with specific mechanical properties for cell cultures, depending on the
polymer type and scaffold architecture. Main synthetic polymers used in tissue engineering include:
Cells 2018, 7, 114 9 of 25
poly (ethylene glycol) (PEG), poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(ε-caprolactone)
(PCL) and their copolymers such as poly(lactide-co-glycolide) (PLGA) [8]. These polymers are
biocompatible and biodegradable and approved by Food and Drug Administration (FDA) for
medical use. New synthetic polymers may also be synthesized, including polyurethanes (PUs),
block copolymers which physical and chemical properties may be tailored varying the composition [87].
For instance, an elastomeric PU scaffold has been recently developed by Chiono et al. as a substrate for
CPC culture [88]. Synthetic biomaterials can be functionalized with ECM proteins or integrin-binding
peptides as well as growth factors to improve cell attachment, proliferation and differentiation,
obtaining “bioartificial” materials [89,90]. Indeed, Boffito et al. have shown that the surface
functionalization of elastomeric PU scaffolds with the cardiac ECM protein laminin-1 enhances CPC
proliferation as well as early differentiation into CMs, smooth muscle cells and endothelial cells and
protects CPCs from apoptosis [91].
In this section, we will review different biomaterial-based approaches improving differentiation of
different stem cell types—ESCs, iPSC, MSCs and CPCs—as well as direct and indirect reprogramming
of fibroblasts into functional mature CMs (Figure 2). Table 1 collects relevant examples of biomaterial
substrates used for the differentiation of stem cells and the direct/indirect reprogramming of somatic
cells to obtain cardiomyocytes, discussed in this critical review article.
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Figure 2. Sche atic representation of C generation. Functional and ature C s can be obtained
starting fro different cell sources: through cardiac differentiation of ste cells (ESCs, iPSCs, SCs
and CPCs) or fibroblast direct and indirect reprogramming into C s. These processes are mainly
guided by differentiation agents (growth factors and small molecules) or reprogramming agents (TFs,
microRNAs and small molecules). Cell differentiation and reprogramming can be performed in the
presence of biomaterials, which are classified as natural (ECM proteins and decellularized cardiac
ECM), synthetic (PLGA, PU, PEG, PCL, etc.) and “bioartificial” (ECM protein-functionalized synthetic
polymers) using a 2D or 3D microenvironment. 3D cell culture offers a structure that mimics natural
microenvironment. Additional stimuli for CM generation can be provided by electrically conductive
materials or electrical and mechanical stimulation in bioreactors and microfluidic devices. Peculiar
features of functional CMs assess the level of CM maturation.
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Table 1. Influence of different biomaterial substrates on stem cell differentiation and fibroblast (direct
and indirect) reprogramming into cardiomyocytes.
Cell Types Substrate Type Main Results References
hESC 3D fibrin/Matrigel hydrogel cardiac tissuepatch vs. 2D fibrin/Matrigel culture
Longer sarcomere length, increased action potential
conduction velocity, expression of cTnT, α-MHC,
SERCA2, CASQ2 and Cx43
Zhang et al.,
2013 [92]
mESCs Mouse decellularized heart ECM vs.liver ECM Increased expression of cTnI, α-MHC and MCL3
Higuchi et al.,
2013 [93]
mESC Collagen Type I blended PLGA electrospunscaffold vs. PLGA and TCP
Acquisition of a spindle-like cardiomyocyte
morphology, expression of α actinin and Cx43
Prabhakaran et
al., 2014 [94]
hESC Fibronectin (70%) and laminin (30%)combination substrate Generation of 60% of cTnI and Nkx2.5 positive cells Sa et al., 2014 [95]
miPSC 3D gelatin-coated electrospun PCLscaffold vs. TCP Increased expression of MESP1, Gata-4, Nkx2.5 and cTnT
Chen et al.,
2015 [96]
hiPSC 2D vs. 3D bovine decellularized cardiacfoetal and adult ECM
3D adult ECM enhanced genes related to calcium
handling (JNC), inward rectifier potassium ion
channels (KCNJ2/Kir2.1), CaV1.2, Cx43 and Myl2
Fong et al.,
2016 [97]
miPSCs
Polyacrylamide gels with different elastic
moduli and functionalized with collagen
Type I, fibronectin and gelatin vs. TCP
Expression of Gata-4, Mef2c and Tbx5 increased on
gelatin/fibronectin-TCP; α-MHC, cTnT and cTnI
increased on Es20 collagen gel.
Hirata et al.,
2018 [98]
hBMSCs Collagen Type V matrix
Expression of both early cardiac genes, such as Gata-4
and Nkx2.5 and their downstream genes, such as α
skeletal actinin, cTnT and cTnC.
Tan et al.,
2010 [99]
hMSCs 3D tissue PECUU fibrous construct vs. TCP Cardiac differentiation with increased expression ofMef2c, Nkx2.5 and Gata-4
Guan et al.,
2011 [100]
mMSCs
Cardiogel (fibroblast-derived ECM
enriched in collagen Type I and III, laminin
and fibronectin)
Approximately 15–20% of mouse BMSCs cultured for
4-weeks on Cardiogel developed three-dimensional
myotubule-like multinucleated structure. Cardiac cell
commitment was further confirmed by the expression
of Gata-4, α-sarcomeric actinin and Cx43.
Santhakumar et al.,
2014 [101]
hMSCs Graphene substrate Enhanced Gata-4, β-MHC, cTnT, Mlc2a, Mlc2v andCx43 expression.
Park et al.,
2014 [102]
hMSCs 3D collagen Type I substrate
Enhanced cardiogenic gene expression compared to TCP
coated with collagen Type I or laminin, which induced
cardiogenic, osteogenic and adipogenic gene expression
Jung et al.,
2016 [103]
hMSCs Collagen Type I 3D patch Increased expression of α-MHC and cTnT Rashedi et al.,2017 [104]
rCPCs Porcine-derived cardiac decellularizedECM vs. collagen matrix
Enhanced proliferation, adhesion and apoptosis
reduction. Increased expression of Nkx2.5, Gata-4,
cTnT and α-MHC
French et al.,
2012 [105]
hCPCs
Biomatrix obtained from adult human
cardiac fibroblasts isolated from healthy
and pathological heart tissues.
Biomatrix stimulated migration and protected cells
from apoptotic processes.
Castaldo et al.,
2013 [106]
hCPCs Polyurethane-based scaffold Scaffold supported in vitro CPC adhesion andviability; it did not support cell proliferation.
Chiono et al.,
2013 [88]
hCPCs 3D collagen-based vs. porcine cardiacECM-based hydrogel.
Cardiac ECM hydrogel enhanced Gata-4, Mlc2v,
Vegfr2 expression in foetal CPCs and Nkx2.5, Mef2c,
CD31, Vegfr2 expression in adult CPCs.
Gaetani et al.,
2016 [107]
hCPC 3D PU-based scaffold with laminin-1surface functionalization
Increased CPC proliferation, decreased CPC apoptosis.
Expression of cardiac markers (Mef2c and α sarcomeric
actinin), smooth muscle cell markers (Gata-6 and SMA)
and endothelial cell markers (ETS1 and FVIII)
Boffito et al.,
2018 [91]
Mouse
embryonic
fibroblasts
(MEFs)
Indirect reprogramming through different
ECM protein based-hydrogels (Matrigel,
collagen Type I and fibrin)
Fibrin hydrogel supported both dedifferentiation and
differentiation phase; collagen Type I /fibrin gel
increased the percentage of contractile colonies.
Kong et al.,
2013 [108]
MEFs
Direct reprogramming using PEG
hydrogels functionalized with laminin and
RGD at different concentration vs. TCP
High concentration of laminin and RGD supported
MEF reprogramming
Smith et al.,
2013 [109]
MEFs,
Tail tip
fibroblasts
(TTFs)
miRNA mediated-direct reprogramming
using fibrin based-3D hydrogels vs. 2D culture
Fibrin based-3D hydrogels supported MEF
reprogramming enhancing α-MHC, cTnI,
α-sarcomeric actinin and Kcnj2 expression; increased
Mef2c, Tbx5 and Hand2 expression in TTFs.
Li et al.,
2016 [110]
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4.1. Role of Substrate on Stem Cell Differentiation into CMs
4.1.1. Biomaterials Supporting ESC Differentiation
Zhang et al. have demonstrated that structural and functional maturation of human ESC-derived
CMs can be enhanced using a 3D culture system [92]. They engineered a cellularized cardiac tissue
patch by culturing human ESC-derived CMs, previously differentiated with an induction medium
containing bone morphogenic protein 4 (BMP4), FGF and activin A, into a 3D hydrogel made of fibrin
and Matrigel. After 2 weeks culture time, CMs in the 3D cardiac patch exhibited longer sarcomere
structures and increased conduction velocity of action potential compared to cells cultured on 2D fibrin
substrates. Moreover, the expression of contractile function-related genes, such as cTnT and α-MHC
and excitation-contraction coupling genes, such as SERCA2 and CASQ2 was upregulated compared to
2D monolayers. In addition, Cx43 expression and the presence of gap junctions suggested functional
electromechanical coupling between cells (Figure 3). The study demonstrated that a 3D biomimetic
microenvironment can greatly enhance ESC differentiation into CMs.
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Reproduced with permission from Zhang et al. Copyright 2018, Publisher Elsevier [92].
Higuchi et al. have reported that mouse decellularized hearts supported mouse ESC
(mESC) differentiation into CMs [93]. mESC-derived CMs, obtained with 5-azacytidine treatment,
an established small drug that induces cardiac differentiation, showed superior expression of cTnI and
α-MHC when cultured for two weeks on cardiac matrix compared to the case of mESCs cultured on
liver decellularized ECM. Moreover, the expression of myosin light chain 3 (Mlc3), one of the myosin
light isoforms involved in regulating cardiac muscle contraction, increased in mESCs cultured on
cardiac ECM compared to liver ECM. Mouse decellularized heart has a different composition c mpared
to liver decellularized matrix as it ontains igher amounts of fibrillin-1, micr fibrillar-associated
protein 2 (Mfap2), microfibrillar-associated protein 5 (Mfap5) and lysyl oxidase homolog 1. In this
study, a 3D ECM-based scaffold with biomimetic composition was found to better stimulate ESC
differentiation into CMs.
Sa et al. have investigated the effect of fibronectin/laminin combinations on the differentiation of ESCs
without using any induction molecule: they found out that fibronectin/laminin 70/30 caused the highest
percentage of differentiation into CMs positive for Nkx2.5 and cTnI after 14 days culture time and proposed
a mechanism based on integrin-mediated MEK/ERK signalling and direct cell-to-cell communication from
distinct cells respectively expressing the laminin and fibronectin integrin receptors [95].
Prabhakaran et a . hav mim cked cardiac ECM u i electrospun PLGA/collage Type I
blend scaffold , which promoted the formation of spindle-like morphology in mESC-derived CMs
compared to control culture conditions on TCPs [94]. Interestingly, cell proliferation increased on
the blend substrate, with cells covering the entire scaffold surface, stimulated by the presence on the
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surface of the ECM protein collagen. Indeed, cells also showed cardiac structural maturation suggested
by the expression of α-actinin and Cx43 after 5 days culture time compared to cells cultured on PLGA
and control TCP substrates.
4.1.2. Biomaterials Supporting iPSC Differentiation
Hirata et al. have coated the surface of polyacrylamide gels having different Young’s moduli (9,
20 and 180 kPa, coded as Es9, Es20 and Es180, respectively) as well as the surface of TCPs with ECM
proteins, such as collagen Type I, fibronectin and gelatin to assess the effect of composition and surface
elasticity on mouse iPSC differentiation into beating CMs [98]. While early cardiac differentiation
genes such as Gata-4, Mef2c and Tbx5 were mostly upregulated on stiff TCPs immobilized with gelatin
or fibronectin, the expression of cardiac contractile protein genes encoding for α-MHC, cTnT and
cTnC was increased only in Es20 polyacrylamide gel immobilized with collagen 14 days after the
initiation of differentiation. Interestingly, cardiac contractile genes were completely suppressed on
iPSCs cultured on Es9-polyacrylamide gel, while the expression of stem cell markers, such as Nanog,
was increased. Results suggested that both matrix elasticity and surface composition strongly affect
cell differentiation.
Fong et al. have studied the influence of both 2D and 3D microenvironments consisting of
foetal and adult bovine cardiac decellularized ECMs on human iPSC-derived CM maturation [97].
Initially, cardiac differentiation of iPSCs was induced regulating Wnt/Gsk3 pathway. 3D adult cardiac
ECM, having high collagen content, and foetal cardiac ECM were found to enhance the expression of
several genes related to cardiac maturation, including genes related to calcium handling (e.g., Junctin)
and to inward rectifier potassium ion channels (KCNJ2/Kir2.1) after seven days culture time, compared
to cells cultured on 2D cardiac ECM. Indeed, these genes were mostly upregulated in cells cultured on
3D adult ECM compared to cells cultured on foetal ECM. Moreover, 3D adult ECM induced a strong
expression of cardiac maturation related genes compared to 2D culture conditions (Cav1.2 and Cx43)
and 3D foetal ECM (myosin light chain 2, Mlc2), suggesting that both biochemical composition and
architecture influence human iPSC-derived CMs maturation.
Chen et al. have evidenced the effects of 3D gelatin-coated PCL nanofibrous scaffolds on the
in vitro differentiation of iPSCs derived from mouse adult fibroblasts into CMs (Figure 4) [96].
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gelatin (upper panel, (A)) used to promote CM differentiation of miPSCs. Gelatin-coated PCL scaffolds 
support miPSC differentiation into CMs, increasing the expression of cTnT and Mlc2a after 15 days 
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Figure 4. Representative image of poly-(ε-caprolactone) (PCL) nanofibrous scaffold coated with gelatin
(upper panel, (A)) used to p omote CM differenti tion of miPSCs. Gelatin-coated PCL scaffolds support
miPSC differentiation into CMs, increasing th expression of cTnT and Mlc2a after 15 days culture time
(lower panels, (B)). Reproduced with permission from Chen et al. [96].
Cells 2018, 7, 114 13 of 25
After 15 days culture time, cells seeded on gelatin-coated PCL electrospun scaffolds showed
increased expression of the early mesoderm marker MESP1 (basic helix-loop-helix transcription factor
mesoderm posterior 1), early cardiac markers Gata-4 and Nkx2.5 and the late cardiac-specific gene for
cTnT compared to cells cultured on TCPs. Moreover, the activation of Wnt/β-catenin signalling in
cells cultured on the 3D PCL nanofibrous scaffolds influenced iPSCs differentiation into CMs during
the early stage of the differentiation process.
4.1.3. Biomaterials Supporting MSC Differentiation
Santhakumar et al. have used Cardiogel for the differentiation of mouse MSCs into cardiac
lineage [101]. Cardiogel has been previously found to improve CM growth and maturation [111].
Mouse heart-derived Cardiogel not only supported mouse bone marrow-derived stem cells (BMSC)
proliferation but also enhanced their cardiac commitment without the addition of external growth
factors or chemical inducers. Approximately 15–20% of mouse BMSCs cultured for 4-weeks on
Cardiogel developed three-dimensional myotubule-like multinucleated structure. Cardiac cell
commitment was further confirmed by the expression of Gata-4, α-sarcomeric actinin and Cx43.
Recently, MSCs have been cultured on 3D collagen Type I scaffolds—already used in clinical
trials for cardiac repair—as an in vitro model of cardiac tissue [104]. MSCs on collagen patches
showed increased expression of cardiomyocyte-specific proteins (although, cells did not reach
a complete functional maturation), secreted higher levels of cardiotrophic factors and developed
a less myofibrogenic phenotype. Additionally, when stimulated with either TLR3 or TLR4 agonists,
MSC expression of pro-inflammatory cytokines was decreased in the presence of the collagen patch.
However, in this study the main effect of collagen sponges on MSC behaviour was attributed to their
tri-dimensionality and biomimetic mechanical properties rather than to their biochemical properties.
Indeed, in previous studies using TCPs pre-coated with collagen Type I or laminin and non-coated
TCPs, human MSCs have shown a similar expression of lineage-specific (cardiogenic, osteogenic
and adipogenic) genes, while the cardiogenic gene expression has been enhanced by MSC culture
in 3D collagen Type I substrates [103]. Similarly, another study has demonstrated that collagen
Type I substrates in the form of hydrogel, sponge, or membrane have a different effect on the
immunosuppressive and paracrine behaviour of MSCs [112]. These studies have suggested that
collagen Type I does not provide specific biochemical cues to promote MSC differentiation into CMs.
Tan et al. have investigated the effect of collagen Type I, III and V matrices and integrin
activation on the regulation of human BMSC commitment to CMs [99]. BMSC-derived CMs
cultured in a myogenic differentiation medium on uncoated TCPs showed increased expression
of collagen-binding α2β1 and α5β3 integrin receptors suggesting that cell interaction with ECM
is crucial for cell differentiation. Indeed, CMs showed enhanced cell adhesion and proliferation
after 1 day when cultured on collagen Type V-coated TCPs compared to either uncoated TCPs or
other collagen Types (I and III). Collagen Type V matrices promoted the expression of both early
cardiac genes, such as Gata-4 and Nkx2.5 and downstream genes, such as Ryanodine receptor 2(RyR2)
involved in calcium release, α-skeletal actinin, cTnT and cTnC. Moreover, cardiac cells generated
on collagen Type V matrices prevented chamber dilatation and improved contractile function when
injected in vivo into the injured myocardium of mouse subjected to MI.
Later, Guan et al. have hypothesized that mimicking 3D cell alignment of myocardium could
enhance cell differentiation [100]. They induced MSC differentiation into cardiac lineage by a tissue
construct engineered by simultaneous electrospinning of poly(ester carbonate urethane)urea (PECUU)
fibres and electrospray of human MSCs. Electrospinning allowed the obtainment of elastomeric
nanofibers mimicking the size and aligned organization of collagen fibres in the myocardium.
Cells integrated in the nanofibrous scaffold showed enhanced cardiac differentiation with a significant
increase in Mef2c and Nkx2.5 gene expression and a strong upregulation of Gata-4 expression
(more than 700 times) compared to monolayer culture, suggesting that cardiac-like structural
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microenvironment can induce cardiac differentiation of MSCs. However, a more pronounced gene
expression was achieved by subjecting scaffolds to mechanical stretching during in vitro culture.
The field of tissue engineering have further investigated the role of other kinds of materials
in regulating cardiomyogenic differentiation of MSCs, such as electrically-conductive graphene-based
substrates. Park et al. have found that cardiomyogenesis-related gene expression is increased in human
MSCs cultured on graphene substrates compared to cells seeded on coverslips [102]. Particularly, graphene
increased the expression of the early cardiac transcription factor Gata-4 and other cardiac-related structural
and functional proteins such as β-MHC, cardiac actinin, cTnT, myosin light chain 2A (Mlc2a) and 2v (Mlc2v)
and Cx43 after 2 weeks culture time. However, CMs generated on graphene substrates did not show
electrophysiological functions, suggesting that additional signals are required for complete CM maturation.
4.1.4. Biomaterials Supporting CPC Differentiation
French et al. have used a decellularized porcine derived-cardiac ECM to examine its ability to support
CPC in vitro differentiation compared to collagen matrix [105]. Culture of CPCs isolated from rat on cardiac
ECM showed increased gene expression of early CM markers such as Nkx2.5, cTnT and α-MHC and
a decreased expression of fibroblast markers such as fibroblast-specific marker 1 (FSP-1) after two days
culture time. In addition, cells seeded on cardiac ECM showed higher Gata-4 protein level after seven days
culture time compared to cells on a collagen matrix. CPCs also showed increased proliferation and adhesion
and a reduction in apoptosis when cultured on cardiac ECM compared to those cultured on collagen matrix.
Gaetani et al. have encapsulated human CPCs, isolated from both foetal and adult patients,
in 3D hydrogels made of collagen Type I or lyophilized decellularized porcine ventricular ECM [107].
Despite both hydrogel types supported foetal and adult cell viability, only myocardial ECM hydrogel
induced significant increase of cardiac gene expression in both foetal CPCs, enhancing expression
of Gata-4, Mlc2v and the vascular marker VEGFR2 and in adult CPCs, with a significant increase
in Nkx2.5, Mef2c, CD31 and VEGFR2, after 4 days culture time. CPCs encapsulated in myocardial
ECM hydrogel also showed increased cell proliferation compared to collagen hydrogel. Moreover,
cell-encapsulated hydrogel based on myocardial matrix could be formed in vivo after injection into
the ventricular wall of healthy rats, representing a promising system for further in vivo studies.
Castaldo et al. have described a method for in vitro production of a human biomatrix, obtained by
adult human cardiac fibroblasts isolated from both healthy and pathological hearts, as a substrate for
culturing human CPCs in vitro [106]. Biomatrix from pathological patients showed increased content
in fibronectin and collagen, which deposition is responsible for scar formation. Biomatrix from healthy
patients stimulated CPCs migration, while both normal and pathological heart-derived biomatrix
protected CPCs from apoptotic processes.
Chiono et al. have recently prepared a three-dimensional biocompatible scaffold by melt-extrusion
additive manufacturing based on a synthesized poly(ester urethane) (PU) with elastomeric-like
behaviour for myocardial tissue applications [88]. The PU scaffold supported in vitro human CPC
adhesion and viability, however it could not stimulate CPC proliferation. For this reason, the PU
scaffold was then surface grafted with a biomatrix protein, laminin-1 and a general adhesion protein,
gelatin [91]. Laminin-1 functionalization could increase CPC proliferation and protect the cells from
apoptosis after 7 and 14 days culture time. Additionally, RT-PCR analysis demonstrated the enhanced
expression of cardiomyocyte (Mef2c and α-sarcomeric actinin), smooth muscle cell (Gata-6 and SMA)
and endothelial cell (ETS1 and FVIII) markers on laminin-1 grafted PU scaffolds especially after 7 days
culture time. This result suggested that the scaffold surface composition alone was able to stimulate
early CPC differentiation compared to control substrates (PU and gelatin coated PU scaffolds).
4.2. Role of Substrate on Fibroblast Direct and Indirect Reprogramming into CMs
Direct as well as indirect reprogramming of fibroblasts into CMs may benefit from the use of
ECM-mimetic substrates to control cell conversion into CMs. One demonstration of the importance
of cardiac microenvironment in cardiac fibroblast direct reprogramming into mature CMs was provided by
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in vivo heart delivery of the TFs Gata-4, Mef2c and Tbx5 (GMT), which improved the direct reprogramming
efficiency of cardiac fibroblasts into CMs, 4 weeks after MI, compared to 2D in vitro culture [113].
Kong et al. have also assessed that indirect reprogramming of MEFs into CMs is influenced by
ECM [108]. MEFs, transduced with polycistronic Oct4-Sox2-Klf4-cMyc lentiviral vector (OSKM) to
obtain progenitors cells and subsequently supplemented with BMP4 to induce cardiac differentiation
were cultured on different natural ECM protein-based hydrogels, such as Matrigel, collagen Type I and
fibrin. Fibrin gels enhanced nearly 4 times the dedifferentiation phase (indicated as the total number
of colonies per cm2) after 7 days culture time and the subsequent differentiation step after 15 days
culture time (indicated as percentage of contractile colonies), compared to Matrigel and collagen
Type I hydrogels. Furthermore, blend hydrogels based on collagen Type I and fibrin induced similar
reprogramming outcomes to pure fibrin hydrogels, while the percentage of contractile colonies out of
the total number of cell colonies was directly proportional to collagen Type I content.
The role of biomaterials in supporting CMs generation has also been investigated in direct
reprogramming approaches. Smith et al. have used PEG hydrogels as a substrate for cell reprogramming
because of its ability to be functionalized with precise concentrations of adhesion molecules or short peptides
avoiding unwanted protein absorption [109]. Cells were cultured in a medium containing Jak-1 inhibitor in
the first step of direct reprogramming and BMP4 for the progress of direct reprogramming. PEG hydrogels
functionalized with high laminin and arginine-glycine-aspartic acid (RGD) peptide concentrations supported
Yamanaka factor-mediated MEF reprogramming, showing higher number of beating cells after 18 days
culture time, compared to TCPs or PEG functionalized with one bioactive molecule (laminin or RGD),
or with laminin and RGD at lower concentrations. Moreover, RT-PCR showed that laminin-functionalized
PEG hydrogels induced higher upregulation of α-sarcomeric actinin and cTnT expression and lower
expression of pluripotency marker Nanog compared to MEFs cultured on TPCs coated with laminin.
Recently, the crucial role of biomimetic biomaterials in regulating cell fate has been investigated in
the direct reprogramming of fibroblasts into cardiomyocyte-like cells using miRNAs [110]. Li et al. have
improved miR combo (miR-1, miR-133, miR-208 and miR-499) mediated direct reprogramming process
of neonatal murine cardiac fibroblasts using a fibrin-based 3D hydrogel containing Matrigel [110].
Fibroblasts transfected with miR combo and encapsulated in 3D hydrogels showed enhanced mRNA
levels of several cardiac genes such as α-MHC, cTnI, α-sarcomeric actinin and Kcnj2 compared to
fibroblasts cultured on traditional 2D culture dishes (Figure 5).
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Figure 5. Representative immunostainings of neonatal cardiac mouse fibroblasts transfected with
miR combo on 2D (A) and 3D (B) environment. 3D fibrin-based hydrogels (right panel) supported
fibroblast reprogramming into CMs increasing α-sarcomeric actinin expression compared to 2D culture
(left panel) after 14 days culture time. Reproduced from Li et al. [110].
Similarly, immunostaining analysis demonstrated that the number of positive cells for cTnT
was increased in 3D versus 2D culture condition. Moreover, the expression of early cardiac TFs was
upregulated in both neonatal cardiac fibroblasts, with increased Mef2c expression and in neonatal TTFs,
showing increased Mef2c, Tbx5 and Hand2 expression, in 3D compared to 2D cell culture environment.
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Furthermore, reprogramming process in 3D hydrogels was shown to be a mechanism dependent on
metalloproteinases (MMPs), which are commonly upregulated in infarcted hearts.
5. Critical Analysis of the State of the Art and Future Perspectives
Stem cell differentiation is generally performed by combinations of soluble factors such as
growth factors and low molecular weight drugs, while direct and indirect reprogramming of
somatic cells is mainly performed by cell transfection with TFs and/or microRNAs via viral or
non-viral vectors to modify gene expression [114,115]. However, cell-ECM interplay, mediated by
the interactions of cell integrin receptors to peptide motifs in ECM proteins has a well-known role in
directing tissue-specific cell functions such as cell adhesion, proliferation, survival, differentiation and
cytoskeleton organization. Traction forces are exerted through integrin receptor-ligand interactions
affecting cell shape and intracellular signalling cascade regulating gene expression. Hence, the interplay
between cells and their substrate may strongly contribute to stem cell fate and cell reprogramming.
Indeed, the induction of differentiation or reprogramming of cells cultured on a suitable biomaterial
substrate may enhance the efficiency and speed of cell conversion and increase the level of cell
functional maturation. The substrate may affect cell differentiation and reprogramming through
its biomimetic biochemical properties and architecture, resulting in tissue-specific mechanical
properties. In general, 3D compared to 2D substrates are preferred as they more closely mimic
the native ECM microenvironment. Based on that, optimal biomaterial substrates should mimic
the chemical and mechanical properties of the ECM naturally hosting all the cells involved in the
differentiation/reprogramming route. Hence, an ideal substrate for differentiation and reprogramming
should combine multiple chemical cues (i) allowing cell viability, attachment and proliferation of
starting cells (stem cells or fibroblasts); (ii) favouring cell differentiation or reprogramming and
(iii) enhancing the attachment and functional maturation of cardiomyocytes. In more detail, in the
case of pluripotent or multipotent stem cells, biomaterials should support adhesion, proliferation
and differentiation of cells as they gradually lose their potency, finally improving the maturation of
differentiated CMs. In the case of indirect reprogramming, the substrate should favour fibroblast as
well as pluripotent stem cell attachment and proliferation and provide the biochemical and mechanical
cues favouring the differentiation and maturation process. Finally, in the case of direct reprogramming
of fibroblasts into CMs, biomaterials should allow fibroblast attachment and proliferation as well as
CM attachment and functional maturation. Based on the literature analysed in this critical review
article, Table 2 collects biomaterial substrates showing favourable biochemical cues for enhanced stem
cell differentiation or fibroblast direct/indirect reprogramming into CMs.
Table 2. Main biomaterial substrates favouring differentiation of stem cells or direct/indirect reprogramming
of fibroblasts into CMs.
Cells Biomaterials for CM Generation
Stem cell differentiation
Pluripotent stem cells:
ESCs Decellularized cardiac ECM [93], fibrin /Matrigel hydrogel [92], collagen Type I [94]—fibronectin/laminin 70/30 hydrogel [95]
iPSCs Decellularized cardiac ECM [97], gelatin [96]—and collagen Type I [98]-coatedscaffolds/hydrogels
Multipotent stem cells:
MSCs Cardiogel [101], collagen Type V substrates [99]
CPCs Decellularized cardiac ECM [105], biomatrix [106], laminin-1 coated scaffolds [91]
Indirect Reprogramming
Fibroblasts Collagen Type I/Fibrin and Fibrin hydrogels [108]
Direct Reprogramming
Fibroblasts Fibrin/Matrigel hydrogel [110], PEG hydrogel containing RGD and laminin [109]
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Table 2 shows that similar substrates have been used to induce ESC and iPSC differentiation into
CMs, such as decellularized cardiac ECM, fibrin-based hydrogel, 3D synthetic scaffolds/hydrogels
coated with collagen Type I or gelatin [92–98]. A recent work by Hirata et al. has shown that biomimetic
stiffness of 3D substrates compared to myocardial tissue (20 kPa) is required to support the expression
of cardiac contractile protein genes during pluripotent stem cell differentiation [98]. Hence, biomimetic
chemical composition and 3D architecture should result in biomimetic mechanical properties for
enhanced support to the differentiation and maturation process.
Similarly, for adult stem cells, a 3D microenvironment providing biomimetic chemical and
mechanical cues may enhance differentiation potential. However, due to the different features (potency
and integrin expression) of pluripotent and multipotent stem cells, specific chemical cues should be
employed. Among multipotent stem cells, MSCs have been commonly differentiated into osteoblasts,
chondrocytes, myocytes and adipocytes [25]. However, their plasticity has also been exploited to
generate other cell types, such as CMs, under the stimulation of a proper culture microenvironment.
For instance, MSCs have been differentiated into CMs when cultured on Cardiogel or collagen
Type V substrates [99,101]. On the other hand, Collagen Type I and laminin have not shown specific
biochemical cues able to induce MSC differentiation into CMs [103,104]. However, 3D substrates based
on collagen Type I with similar mechanical properties to the native myocardium have enhanced MSC
differentiation into CMs [104]. Considering MSC plasticity and their possibility to differentiate into
different cell types, biochemical cues should be properly combined with other cues, such as substrate
biomimetic stiffness, electrically conductive materials (e.g., graphene-based composites) and dynamic
cell culture conditions (e.g., mechanical stretching) to promote MSC differentiation into CMs [100,102].
Compared to MSCs, CPCs are naturally committed to regenerate myocardial tissue. CPC differentiation
into CMs has been favoured by culturing the cells on decellularized heart ECM, biomatrix-based
substrates, as well as on scaffolds functionalized with laminin-1 [91,105,106]. Laminin-1 is the laminin
form predominating in the heart tissue during early embryogenesis and further organogenesis and it
is re-expressed in heart regeneration following tissue damage [116,117]. Studies on the interaction of
CPCs with cardiac ECM constituent proteins have shown that laminin-1 protects CPCs from apoptosis
and stimulates their proliferation [117]. Recent studies have also demonstrated that laminin-1 enhances
CPC differentiation [91]. Hence, it represents an ideal biomimetic protein for stimulating CPC viability,
proliferation, as well as differentiation into CMs as an alternative to complex cardiac ECM-based substrates.
Finally, fibroblast direct reprogramming is one of the most recent strategies investigated for CM
generation. Despite the early promising results, the direct reprogramming of human adult fibroblasts
into mature CMs still represents a challenge [40]. Only few studies have investigated the role of 3D
biomaterial substrates, such as fibrin/Matrigel hydrogels and PEG-based hydrogels containing laminin
and RGD, in direct reprogramming of fibroblasts into CMs [109,110]. Such studies have evidenced that
the reprogramming efficiency and CM maturation may be significantly improved in 3D biomimetic
substrates. On the other hand, several studies have demonstrated that traditional 2D in vitro tests
have underestimated the efficiency of direct reprogramming compared to in vivo trials in mouse
model [14]. This suggests that 2D TCPs fail in recapitulating the complexity of the native cardiac
tissue and indirectly demonstrates that 3D biomimetic substrates may enhance direct reprogramming.
Based on that, 3D in vitro models of human cardiac tissue are demanded to predict in vivo direct
reprogramming efficiency. Additionally, 3D biomimetic substrates may represent a valid tool to
enhance both in vitro and in vivo direct reprogramming of fibroblasts into CMs and to increase
the functional maturation level of CMs, greatly improving the clinical potentialities of the direct
reprogramming approach.
Among the different strategies for myocardial regeneration and treatment, the use of iPSCs as
cellular source is promising as it would allow patient-specific therapy as well as in vitro modelling
of cardiac tissue. Similarly, direct reprogramming of human fibroblasts into CMs deserves future
investigation as a new intriguing possibility for MI treatment by the in situ conversion of fibrotic scar
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(populated by cardiac fibroblasts) into contractile tissue. Additionally, direct reprogramming approach
may also be exploited for CM generation in vitro for cardiac tissue modelling as well as cell therapy.
Biochemical cues represent important stimuli to promote the formation of fully mature human
adult CMs with high efficiency. One effective method to discriminate the influence of biochemical
composition on cell differentiation and reprogramming is to perform in vitro differentiation and
reprogramming experiments on 2D TCPs coated with different biomolecules. Indeed, such experiments
allow the selection of biomimetic molecules for the subsequent production or functionalization of 3D
scaffolds aimed at inducing stem cell differentiation or fibroblast reprogramming into CMs. On the
other hand, 3D scaffolds combine biochemical, structural and mechanical cues which in synergy
affect cell behaviour. Additionally, bioreactors and microfluidic devices (Figure 6) may be used for
the in vitro culture of cells on scaffolds or hydrogels under mechanical and/or electrical stimulation,
in dynamic flow conditions simulating the native microenvironment [118].
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Particularly, biomimetic high-throughput microfluidic devices have been recently proposed to study 
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mechanical cues [5]. Such devices have the inherent advantage to make use of a moderate number of 
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Figure 6. Microfluidic platform developed to study the effect of biochemical, mechanical and electrical
stimulations for stem cell differentiation: (A) Schematic view; (B) cross-section view in unstimulated
configuration; (C) cross-section view in stimulated configuration. The central channel (in red) is the
media channel providing nutrients and soluble factors to cells. The pneumatic channels (in light
blue) perform mechanical stimulation by stretching the poly(dimethylsiloxane) (PDMS) membrane
(yellow arrows) where the cells are cultured. The electrically conductive layer (in light grey) is based
on two regions composed of PDMS and carbon nanotubes (CNT) mixture, connected to the stimulator
by two external gold-coated connectors (in red and black). Reproduced from Pavesi et al. [5].
Such physical stimulation may further enhance differenti tion a d reprogramming into CMs.
Particularly, biomimetic high-throughput microfluidic devices have been recently proposed to study
stem cell differentiation in dynamic conditions in the presence of biochemical, electrical and mechanical
cues [5]. Such devices have the inherent advantage to make use of a moderate number of cells and to
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provide a biomimetic culture microenvironment for the selection of hydrogels with proper chemical
and mechanical properties for stem cell differentiation into CMs. Additionally, microfluidic systems
are compatible with the common techniques used for evaluating cell differentiation or reprogramming
such as immunocytochemistry and RT-PCR analysis. In the next future, microfluidic systems could be
extended to the study of direct reprogramming of fibroblasts into CMs, representing a valid tool for
the selection of proper biomaterial substrates and physical stimuli (e.g., mechanical stretching and
electrical stimulation) for the efficient fibroblast conversion into mature CMs.
Interestingly, the wide knowledge available from experiments on stem cells differentiation
into CMs could be effectively extended to the new of field direct reprogramming, speeding up the
maturation of such promising technique in the perspective of future clinical applications.
As a conclusion, generation of mature human adult CMs from stem cell differentiation or fibroblast
reprogramming still represents a challenge and further studies are needed to understand the processes
underlying the low efficiency of cell conversion, as well as the incomplete maturation of CMs.
A multidisciplinary approach involving the combination of multiple cues in the cell microenvironment
may represent a valid tool to find out the optimal conditions for stem cell differentiation and fibroblast
reprogramming into CMs.
6. Conclusions
The field of cardiac tissue engineering is rapidly evolving to find out regenerative therapies to treat
myocardial fibrosis and dysfunction after MI. Among the possible routes, indirect and direct fibroblast
reprogramming strategies into CMs represent interesting approaches and deserve future investigation
in the perspective of possible clinical applications. Biochemical composition of the culture substrate
represents one valid tool to overcome the low conversion efficiency into CMs and the low maturation
stage of CMs generated by differentiation or direct reprogramming approaches. Indeed, knowledge
arising from previous studies on the differentiation of ESCs and adult stem cells can be exploited
to engineer biomimetic 3D substrates for efficient indirect and direct fibroblast reprogramming into
mature CMs. Human or animal-derived ECM materials, such as decellularized cardiac ECM, Cardiogel,
Matrigel and biomatrix have been frequently used for stem cell differentiation [2]. Although such
complex materials have been found to enhance stem cell differentiation into CMs, their allogenic or
xenogenic nature makes them potentially immunogenic. Additionally, natural materials, including
collagen and fibrin, suffer from limitations such as batch-to-batch variation, low mechanical resistance
and fast degradation rate. On the other hand, “bioartificial” substrates in the form of synthetic scaffolds
or hydrogels functionalized with adhesive peptides or biomimetic proteins may represent a valid
alternative, thanks to their reproducibility, scalability and biomimicry. Furthermore, synthetic polymer
chemistry, hydrogel crosslinking degree and scaffold architecture may be easily tailored to obtain
3D substrates with biomimetic mechanical stiffness and geometry, which together with the surface
chemical composition may act in synergy to promote efficient indirect and direct reprogramming into
functional CMs. Finally, a full micro-environmental control of the differentiation and reprogramming
process in terms of biochemical, bio-mechanical and electrical cues is demanded to further stimulate
maturation and structural organization of the cardiac micro-tissue deriving from differentiation or
reprogramming approaches.
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